clostridium botulinum neurotoxin serotype A recombinant (IPN59011) / Ipsen - LARVOL DELTA

LONG-SET: Study to Evaluate the Safety and Efficacy of IPN59011 in Improving the Appearance of Moderate to Severe Upper Facial Lines. (clinicaltrials.gov) - P1 | N=56 | Terminated | Sponsor: Ipsen | Phase classification: P1/2 ➔ P1

Phase classification

Drooling in PD HD 720p (YouTube) - "In conclusion, botulinum toxin is a safe and effective treatment for drooling in PD that can improve the quality of life of people with this condition. It has advantages over oral anticholinergic medications, which can cause cognitive and psychiatric side effects that are detrimental for people with PD."

Video

LONG-SET: Study to Evaluate the Safety and Efficacy of IPN59011 in Improving the Appearance of Moderate to Severe Upper Facial Lines. (clinicaltrials.gov) - P1/2 | N=56 | Terminated | Sponsor: Ipsen | N=412 ➔ 56 | Trial completion date: Dec 2023 ➔ Oct 2022 | Active, not recruiting ➔ Terminated | Trial primary completion date: Dec 2023 ➔ Oct 2022; Sponsor terminated the study due to strategic considerations

Enrollment change • Trial completion date • Trial primary completion date • Trial termination

LONG-SET: Study to Evaluate the Safety and Efficacy of IPN59011 in Improving the Appearance of Moderate to Severe Upper Facial Lines. (clinicaltrials.gov) - P1/2 | N=412 | Active, not recruiting | Sponsor: Ipsen | Recruiting ➔ Active, not recruiting

Enrollment closed